![At ODAC without sponsors, FDA highlights safety signals in PI3K inhibitor trials](https://cdn.cancerletter.com/media/2022/04/15145421/48-15-FDA-4x3-1.jpg)
![At ODAC without sponsors, FDA highlights safety signals in PI3K inhibitor trials](https://cdn.cancerletter.com/media/2022/04/15145421/48-15-FDA-4x3-1.jpg)
Cover Story
Conversation with The Cancer Letter
Why is the April 21 ODAC different from all the other ODACs? At all other ODACs, a commercial sponsor gets to make a case. On April 21, only FDA’s voice will be heard.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - Before the Olympics were smoke-free, tobacco brand deals ran rampant
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access - Georgetown-MedStar: Patients with cancer can rely on our lawyers to fight legal issues that harm health
- How a Georgetown med school student found her calling in surgery, law, and health equity